Literature DB >> 25118874

Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Renátó Kovács1, Rudolf Gesztelyi, David S Perlin, Gábor Kardos, Marianna Domán, Réka Berényi, László Majoros.   

Abstract

It was previously demonstrated that brief (≤1 h) exposures to echinocandins are as effective to kill Candida albicans cells as continuous 24-h exposure. However, killing rates after continuous and short (1 h) echinocandin exposures to C. albicans have not yet been evaluated in RPMI-1640 with and without 50 % serum. We evaluated four echinocandin susceptible C. albicans bloodstream isolates, ATCC 10231 type strain and an echinocandin-resistant isolate (DPL20, FKS F645P). Caspofungin MICs, time-kill and postantifungal effect (PAFE) tests were performed in RPMI-1640 with and without 50 % serum. Killing rates (k values) in time-kill and PAFE experiments were determined for each strain and concentration. In time-kill experiments, colony count decreases were isolate- and concentration-dependent at 0.25, 1, 4, 8, 16 and 32 mg/L in RPMI-1640, but concentration-independent at 1, 4, 8, 16 and 32 mg/L in 50 % serum. One-hour caspofungin exposure at 4, 16 and 32 mg/L resulted in CFU decreases comparable with the results obtained in time-kill experiments in RPMI-1640, but 50 % serum at 4, 16 and 32 mg/L allowed growth of all isolates (k values were negative) (P < 0.05-0.001). PAFE in 50 % serum decreased markedly at 4, 16 and 32 mg/L. Killing rates remained high and concentration-independent in 50 % serum in case of continuous but not in case of brief caspofungin exposure. As only a short growth inhibition without killing was observed in 50 % serum, clinical relevance of caspofungin PAFE in vivo is questionable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25118874     DOI: 10.1007/s11046-014-9799-4

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  13 in total

1.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

Authors:  Ryan K Shields; M Hong Nguyen; Chen Du; Ellen Press; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 3.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

4.  Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Authors:  Cornelius J Clancy; Hong Huang; Shaoji Cheng; Hartmut Derendorf; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  Phase II dose escalation study of caspofungin for invasive Aspergillosis.

Authors:  O A Cornely; J J Vehreschild; M J G T Vehreschild; G Würthwein; D Arenz; S Schwartz; C P Heussel; G Silling; M Mahne; J Franklin; U Harnischmacher; A Wilkens; F Farowski; M Karthaus; T Lehrnbecher; A J Ullmann; M Hallek; A H Groll
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

7.  Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates.

Authors:  Katherine T Nguyen; Philip Ta; Bich Thu Hoang; Shaoji Cheng; Binghua Hao; M Hong Nguyen; Cornelius J Clancy
Journal:  Int J Antimicrob Agents       Date:  2009-11-04       Impact factor: 5.283

8.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

9.  Elevated chitin content reduces the susceptibility of Candida species to caspofungin.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

10.  Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification.

Authors:  Z Szabó; B Tóth; M Kovács; G Kardos; A Maráz; F Rozgonyi; L Majoros
Journal:  J Clin Microbiol       Date:  2008-03-05       Impact factor: 5.948

View more
  3 in total

1.  Dose escalation studies with caspofungin against Candida glabrata.

Authors:  Marianna Domán; Renátó Kovács; David S Perlin; Gábor Kardos; Rudolf Gesztelyi; Béla Juhász; Aliz Bozó; László Majoros
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

2.  Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.

Authors:  Sandra Gil-Alonso; Nerea Jauregizar; Elena Eraso; Guillermo Quindós
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

Review 3.  Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

Authors:  Nerea Jauregizar; Guillermo Quindós; Sandra Gil-Alonso; Elena Suárez; Elena Sevillano; Elena Eraso
Journal:  J Fungi (Basel)       Date:  2022-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.